Our top pick for
Greenlight Capital Re, Ltd is an insurance-reinsurance business based in the US. Greenlight Capital Re shares (GLRE) are listed on the NASDAQ and all prices are listed in US Dollars. Greenlight Capital Re employs 40 staff and has a trailing 12-month revenue of around USD$413.6 million.
|52-week range||USD$5 - USD$10.22|
|50-day moving average||USD$7.8888|
|200-day moving average||USD$7.4112|
|Wall St. target price||USD$1|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-4.198|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing Greenlight Capital Re stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Greenlight Capital Re's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Greenlight Capital Re's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 2.38. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Greenlight Capital Re's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Greenlight Capital Re's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$7.6 million.
The EBITDA is a measure of a Greenlight Capital Re's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||USD$413.6 million|
|Gross profit TTM||USD$37.4 million|
|Return on assets TTM||-2.9%|
|Return on equity TTM||-14.68%|
|Market capitalisation||USD$281.9 million|
TTM: trailing 12 months
There are currently 2.3 million Greenlight Capital Re shares held short by investors – that's known as Greenlight Capital Re's "short interest". This figure is 14.9% up from 2.0 million last month.
There are a few different ways that this level of interest in shorting Greenlight Capital Re shares can be evaluated.
Greenlight Capital Re's "short interest ratio" (SIR) is the quantity of Greenlight Capital Re shares currently shorted divided by the average quantity of Greenlight Capital Re shares traded daily (recently around 207415.7943067). Greenlight Capital Re's SIR currently stands at 10.89. In other words for every 100,000 Greenlight Capital Re shares traded daily on the market, roughly 10890 shares are currently held short.
However Greenlight Capital Re's short interest can also be evaluated against the total number of Greenlight Capital Re shares, or, against the total number of tradable Greenlight Capital Re shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Greenlight Capital Re's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Greenlight Capital Re shares in existence, roughly 60 shares are currently held short) or 0.0837% of the tradable shares (for every 100,000 tradable Greenlight Capital Re shares, roughly 84 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Greenlight Capital Re.
Find out more about how you can short Greenlight Capital Re stock.
We're not expecting Greenlight Capital Re to pay a dividend over the next 12 months.
Over the last 12 months, Greenlight Capital Re's shares have ranged in value from as little as $5 up to $10.22. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Greenlight Capital Re's is 1.2871. This would suggest that Greenlight Capital Re's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Greenlight Capital Re, Ltd., through its subsidiaries, operates as a property and casualty reinsurer worldwide. The company offers various property reinsurance products and services, including automobile physical damage; personal lines, such as homeowners' insurance; and commercial lines. It also provides casualty reinsurance products and services comprising general liability, motor liability, professional liability, and worker's compensation; and accident and health, mortgage insurance, surety, trade credit, marine, aviation, crop, energy, cyber, and terrorism products. The company markets its products through reinsurance brokers. Greenlight Capital Re, Ltd. was founded in 2004 and is headquartered in Grand Cayman, the Cayman Islands.
Everything we know about the Toast Inc IPO, plus information on how to buy in.
Everything we know about the Cyxtera IPO, plus information on how to buy in.
Everything we know about the ATI Physical Therapy IPO, plus information on how to buy in.
Everything we know about the Sportradar IPO, plus information on how to buy in.
Everything we know about the Longboard Pharmaceuticals Inc IPO, plus information on how to buy in.
Everything we know about the Prometheus Biosciences Inc IPO, plus information on how to buy in.
Everything we know about the Olo Inc IPO, plus information on how to buy in.
Everything we know about the China Eco-Materials Group Co Limited IPO, plus information on how to buy in.
Everything we know about the Gain Therapeutics Inc IPO, plus information on how to buy in.
Everything we know about the Karat Packaging Inc IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.